Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses

Vaccination plays a pivotal role in the control and prevention of animal infectious diseases. However, no efficient and safe universal vaccines are currently registered for major pathogens such as influenza A virus, foot-and-mouth disease virus (FMDV), simian immunodeficiency virus (SIV), and small...

Descripción completa

Detalles Bibliográficos
Autores: Gómez, Álex, Reina, Ramsés
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/406008
Acceso en línea:http://hdl.handle.net/10261/406008
https://api.elsevier.com/content/abstract/scopus_id/105006655280
Access Level:acceso abierto
Palabra clave:Sendai virus vector
Animals
Immune response
Vaccine
id ES_5d3bbc7860291a538fe7fd5c8f9aca00
oai_identifier_str oai:digital.csic.es:10261/406008
network_acronym_str ES
network_name_str España
repository_id_str
spelling Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal VirusesGómez, ÁlexReina, RamsésSendai virus vectorAnimalsImmune responseVaccineVaccination plays a pivotal role in the control and prevention of animal infectious diseases. However, no efficient and safe universal vaccines are currently registered for major pathogens such as influenza A virus, foot-and-mouth disease virus (FMDV), simian immunodeficiency virus (SIV), and small ruminant lentiviruses (SRLV). Here, we review the development of Sendai virus (SeV) vectors as a promising vaccine platform for animal diseases. Recombinant SeV vectors (rSeVv) possess several key features that make them highly suitable for developing vaccination strategies: (1) SeV has exclusively cytoplasmic replication cycle, therefore incapable of transforming host cells by integrating into the cellular genome, (2) rSeVv can accommodate large foreign gene/s inserts (~5 kb) with strong but adjustable transgene expression, (3) can be propagated to high titers in both embryonated chicken eggs and mammalian cell lines, (4) exhibits potent infectivity across a broad range of mammalian cells from different animals species, (5) undergo transient replication in the upper and lower respiratory tracts of non-natural hosts, (6) has not been associated with disease in pigs, non-humans primates, and small ruminants, ensuring a favorable safety profile, and (7) induce a robust innate and cellular immune responses. Preclinical and clinical studies using rSeVv-based vaccines against influenza A virus, FMDV, SIV, and SRLV have yielded promising results. Therefore, this review highlights the potential of rSeVv-based vaccine platforms as a valuable strategy for combating animal viruses.This research was funded by the Gobierno de Navarra, grant number PC24-ECTIVAC-002-017-018.Peer reviewedMultidisciplinary Digital Publishing InstituteDiputación Foral de NavarraGómez, Álex [0000-0002-9723-9004]Reina, Ramsés [0000-0003-1265-9139]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202520252025info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/406008https://api.elsevier.com/content/abstract/scopus_id/105006655280reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://doi.org/10.3390/v17050737Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/4060082026-05-22T06:33:51Z
dc.title.none.fl_str_mv Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses
title Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses
spellingShingle Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses
Gómez, Álex
Sendai virus vector
Animals
Immune response
Vaccine
title_short Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses
title_full Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses
title_fullStr Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses
title_full_unstemmed Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses
title_sort Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses
dc.creator.none.fl_str_mv Gómez, Álex
Reina, Ramsés
author Gómez, Álex
author_facet Gómez, Álex
Reina, Ramsés
author_role author
author2 Reina, Ramsés
author2_role author
dc.contributor.none.fl_str_mv Diputación Foral de Navarra
Gómez, Álex [0000-0002-9723-9004]
Reina, Ramsés [0000-0003-1265-9139]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Sendai virus vector
Animals
Immune response
Vaccine
topic Sendai virus vector
Animals
Immune response
Vaccine
description Vaccination plays a pivotal role in the control and prevention of animal infectious diseases. However, no efficient and safe universal vaccines are currently registered for major pathogens such as influenza A virus, foot-and-mouth disease virus (FMDV), simian immunodeficiency virus (SIV), and small ruminant lentiviruses (SRLV). Here, we review the development of Sendai virus (SeV) vectors as a promising vaccine platform for animal diseases. Recombinant SeV vectors (rSeVv) possess several key features that make them highly suitable for developing vaccination strategies: (1) SeV has exclusively cytoplasmic replication cycle, therefore incapable of transforming host cells by integrating into the cellular genome, (2) rSeVv can accommodate large foreign gene/s inserts (~5 kb) with strong but adjustable transgene expression, (3) can be propagated to high titers in both embryonated chicken eggs and mammalian cell lines, (4) exhibits potent infectivity across a broad range of mammalian cells from different animals species, (5) undergo transient replication in the upper and lower respiratory tracts of non-natural hosts, (6) has not been associated with disease in pigs, non-humans primates, and small ruminants, ensuring a favorable safety profile, and (7) induce a robust innate and cellular immune responses. Preclinical and clinical studies using rSeVv-based vaccines against influenza A virus, FMDV, SIV, and SRLV have yielded promising results. Therefore, this review highlights the potential of rSeVv-based vaccine platforms as a valuable strategy for combating animal viruses.
publishDate 2025
dc.date.none.fl_str_mv 2025
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/406008
https://api.elsevier.com/content/abstract/scopus_id/105006655280
url http://hdl.handle.net/10261/406008
https://api.elsevier.com/content/abstract/scopus_id/105006655280
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.3390/v17050737
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408999206551552
score 15.811543

Similares en LA Referencia